Published in Genetics and Environmental Law Weekly, October 7th, 2006
The following are excerpts from the company's update:
Qiaer Biotechnology recently completed phase I trials of the genetic cancer treatment drug Rh-Apo2L. Rh-Apo2L is a new drug therapy using a recombinant protein produced by genetic engineering, called human Apo2L which can cause cell apoptosis - cellular death - by triggering points on the receptors in the cells of tumors. Scientists believe that cancer cells may resist or not activate apoptosis, thus continuing to grow and divide uncontrollably...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.